<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41457" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ocrelizumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Flynn</surname>
            <given-names>James P.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Flynn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41457.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ocrelizumab is a medication used in the management and treatment of primary progressive and relapsing multiple sclerosis. It is in the anti-CD20 monoclonal antibody class of medications. This activity describes the indications, action, and contraindications for ocrelizumab as a valuable agent in multiple sclerosis management. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., administration, contraindications, monitoring, toxicity) pertinent for interprofessional team members in the care of patients with multiple sclerosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ocrelizumab.</p></list-item><list-item><p>Describe the possible adverse effects of ocrelizumab.</p></list-item><list-item><p>Review the toxicity of ocrelizumab.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance ocrelizumab and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41457&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41457">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41457.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ocrelizumab is an FDA-approved CD20-directed humanized monoclonal antibody indicated to treat adult patients with primary progressive or relapsing multiple sclerosis; it received approval from the FDA on March 28, 2017.&#x000a0;</p>
        <p>FDA-approved indications (with clinical trial summaries):</p>
        <p>
<bold>Multiple Sclerosis (MS)</bold>
</p>
        <p>
<bold>Primary-Progressive MS</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ORATORIO study: In this double-blinded study, 732 patients were randomly assigned 2 to 1 to either ocrelizumab (two intravenous 300 mg doses given 14 days apart every 24 weeks) or placebo for at least 120 weeks until a prespecified number of disability events occurred. The study's primary endpoint was the percentage of patients with 12-week confirmed disability progression.&#x000a0; Ocrelizumab showed a 12-week confirmed disability progression of 32.9%, whereas the placebo arm showed a 39.3% rate (hazard ratio = 0.76, p=0.03).<xref ref-type="bibr" rid="article-41457.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Relapsing MS</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>OPERA I study: In this double-blinded study, 821 patients were randomly assigned 1 to 1 to either ocrelizumab (two intravenous 300 mg doses given 14 days apart and then a single 600 mg doses every 24 weeks) or interferon beta-1a (subcutaneous 44 microgram dose three times weekly) for 96 weeks with a primary endpoint of annualized relapse rate. Results showed that ocrelizumab has a statistically significantly lower annualized relapse rate at 0.16 vs. interferon beta-1a at 0.29 (46% reduction, p&#x0003c;0.001).<xref ref-type="bibr" rid="article-41457.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>OPERA II study: In this double-blinded study, 835 patients were randomly assigned 1:1 to either Ocrelizumab(two intravenous 300mg doses given 14 days apart and then a single 600mg dose every 24 weeks) or interferon beta-1a (subcutaneous 44 microgram dose three times weekly) for 96 weeks with a primary endpoint of annualized relapse rate. Results showed that ocrelizumab has a statistically significantly lower annualized relapse rate at 0.16 vs. Interferon beta-1a at 0.29 (47% reduction, p&#x0003c;0.001).<xref ref-type="bibr" rid="article-41457.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>At the time of launch, ocrelizumab had a list price of $65000 annually. It is generally covered by commercial insurance and by Medicare. The manufacturer provides patient payment assistance in the form of a co-pay program and referrals to a patient payment assistance foundation.</p>
      </sec>
      <sec id="article-41457.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ocrelizumab is a second-generation anti-CD20 recombinant monoclonal antibody with a molecular mass of 145kDa. It is a follow-up to the anti-CD20 monoclonal antibody rituximab but with a humanized IgG1 tail.<xref ref-type="bibr" rid="article-41457.r3">[3]</xref> Humanization of the antibody is expected to reduce antigenicity and improve CD20 binding.<xref ref-type="bibr" rid="article-41457.r4">[4]</xref> CD20 is a phosphoprotein expressed on a broad range of human B-cells. However, it is not present in the early lineage (stem cells and pro-B-cells) or late lineage (plasmablasts and plasma cells).<xref ref-type="bibr" rid="article-41457.r5">[5]</xref> Ocrelizumab binds to CD20 on B-lymphocytes leading to antibody-dependent cellular cytolysis and complement-mediated lysis.<xref ref-type="bibr" rid="article-41457.r6">[6]</xref> While the precise method by which ocrelizumab exerts its effect on multiple sclerosis is unknown, it depletes B-cells which are thought to affect the pathogenesis of multiple sclerosis using cytokine regulation, antigen presentation, autoantibody production.<xref ref-type="bibr" rid="article-41457.r2">[2]</xref></p>
      </sec>
      <sec id="article-41457.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ocrelizumab is FDA-approved for intravenous infusion. It is supplied in 300 mg/mL single-dose vials. The initial dose is given as a 300 mg intravenous infusion over 2.5 hours, followed up with an additional 300 mg intravenous infusion 14 days later. Subsequent doses are given every six months as a 600 mg intravenous infusion over 3.5 hours.&#x000a0; Maintenance doses of ocrelizumab should be at a minimum of five months apart. Some argue that dosing should not be on a fixed schedule but based on CD19/20 counts to optimize dosing to minimize unnecessary patient exposure and allow for significant cost savings.<xref ref-type="bibr" rid="article-41457.r7">[7]</xref> For mild to moderate adverse events, a reduction in infusion rate is indicated if tolerated. Severe and life-threatening reactions indicate interruption or discontinuation of the drug.&#x000a0;</p>
      </sec>
      <sec id="article-41457.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse reactions in relapsing multiple sclerosis with an incidence of more than 5% and higher than interferon beta-1a<xref ref-type="bibr" rid="article-41457.r2">[2]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Back pain</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Herpes virus-associated infections</p>
          </list-item>
          <list-item>
            <p>Infusion reactions</p>
          </list-item>
          <list-item>
            <p>Lower respiratory infections</p>
          </list-item>
          <list-item>
            <p>Pain in extremities</p>
          </list-item>
          <list-item>
            <p>Upper respiratory infections&#x000a0;</p>
          </list-item>
        </list>
        <p>Adverse reactions in primary progressive multiple sclerosis with an incidence of more the 5% and higher than placebo<xref ref-type="bibr" rid="article-41457.r1">[1]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cough</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Edema peripheral</p>
          </list-item>
          <list-item>
            <p>Herpes virus-associated infections</p>
          </list-item>
          <list-item>
            <p>Infusion reactions</p>
          </list-item>
          <list-item>
            <p>Lower respiratory tract infections</p>
          </list-item>
          <list-item>
            <p>Skin reactions</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract infections</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41457.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ocrelizumab is contraindicated in the following patients:</p>
        <list list-type="bullet">
          <list-item>
            <p>Those with a history of life-threatening infusion reactions to ocrelizumab</p>
          </list-item>
          <list-item>
            <p>Patients with active hepatitis-B infection</p>
          </list-item>
        </list>
        <p>Before initiating ocrelizumab:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatitis B virus screening is necessary. There have been reports of ocrelizumab leading to reactivation of latent HBV in a previously resolved patient.<xref ref-type="bibr" rid="article-41457.r8">[8]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>All necessary immunizations should be given at least six weeks before initiating ocrelizumab, given the expected B-cell depletion.</p>
          </list-item>
          <list-item>
            <p>Consider previous immunosuppressive therapy for potential increased immunosuppressive effects.</p>
          </list-item>
        </list>
        <p>Before every ocrelizumab infusion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Determine if there is an active infection; if yes, delay infusion until resolution</p>
          </list-item>
          <list-item>
            <p>Premedicate with 100 mg of methylprednisolone and an antihistamine 30 minutes before infusion</p>
          </list-item>
          <list-item>
            <p>Consider premedication with an antipyretic</p>
          </list-item>
          <list-item>
            <p>A regiment of cetirizine (10 mg), ranitidine (75 mg), increased hydration, IV diphenhydramine (50 mg), IV methylprednisolone (125 mg), and oral acetaminophen (650 mg) has been shown to reduce infusion reactions by 60% in one study.<xref ref-type="bibr" rid="article-41457.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41457.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before initiating ocrelizumab therapy, hepatitis B virus screening is indicated.&#x000a0;</p>
        <p>Patients receiving an ocrelizumab infusion will require monitoring for at least the next hour for the following signs and symptoms of refusion reactions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Coughing or wheezing</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Fast heart rate</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Feeling faint</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Hives</p>
          </list-item>
          <list-item>
            <p>Itchy skin</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Shortness of breath</p>
          </list-item>
          <list-item>
            <p>Swelling of throat</p>
          </list-item>
          <list-item>
            <p>Throat irritation or pain</p>
          </list-item>
          <list-item>
            <p>Tiredness</p>
          </list-item>
          <list-item>
            <p>Trouble breathing</p>
          </list-item>
        </list>
        <p>In clinical trials, there was an incidence of life-threatening bronchospasm (which recovered with treatment) with the initial infusion of ocrelizumab.<xref ref-type="bibr" rid="article-41457.r2">[2]</xref></p>
      </sec>
      <sec id="article-41457.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Pregnancy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>There is inadequate data on the fetal risk associated with ocrelizumab use in pregnancy.</p>
          </list-item>
          <list-item>
            <p>Ocrelizumab is an antibody of immunoglobulin G1 subtype, which is known to cross the placental barrier.</p>
          </list-item>
          <list-item>
            <p>Administration of ocrelizumab to pregnant monkeys at 2 to 10 times the recommended human dose has shown increased perinatal mortality and depletion of B-cell populations. Offspring were observed to have bone marrow, renal, and testicular toxicities not seen in the mother.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>While data on ocrelizumab exposure during pregnancy is sparse, rituximab use (as a proxy) has shown B-cell depletion in delivered babies.<xref ref-type="bibr" rid="article-41457.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Other</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No data shows the existence of ocrelizumab in human milk; animal studies have shown its presence in monkey milk. However, large molecules like monoclonal antibodies are unlikely to be excreted into human breast milk or absorbed into the baby&#x02019;s circulation in any significant amount.<xref ref-type="bibr" rid="article-41457.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Ocrelizumab&#x02019;s safety and efficacy have not been established in pediatric patients.</p>
          </list-item>
          <list-item>
            <p>Ocrelizumab&#x02019;s safety and efficacy have not been established in patients over 65 years old.</p>
          </list-item>
          <list-item>
            <p>In clinical studies of ocrelizumab, there were six cases of breast cancer as compared to none in the placebo or interferon beta-1a groups.<xref ref-type="bibr" rid="article-41457.r1">[1]</xref><xref ref-type="bibr" rid="article-41457.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41457.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ocrelizumab is a new biological agent, and even though it has shown a positive risk/benefit trade-off in clinical trials, it does require close monitoring for safety; thus, besides the prescribing clinician, both nurses and pharmacists are responsible for educating the patient on the potential side effects of the drug.</p>
        <p>During IV administration, the drug has shown infusion reactions in more than one-third of patients; therefore, it is essential to monitor side effects such as coughing, dizziness, fast heart rate, fatigue, feeling faint, fever, flushing, headache, hives, itchy skin, nausea, rash, shortness of breath, swelling of the throat, throat irritation or pain, tiredness, trouble breathing and wheezing. In clinical trials, there was an incidence of life-threatening bronchospasm (which recovered with treatment) during the initial infusion of ocrelizumab.<xref ref-type="bibr" rid="article-41457.r2">[2]</xref> Therefore, because the drug can trigger a life-threatening infusion reaction, the interprofessional team needs to have the necessary medications and equipment in the room to ensure safe outcomes.</p>
        <p>Since some adverse effects are delayed-onset, including opportunistic infections and malignancies, an outpatient neurology nurse should continue to follow the patients and coordinate additional surveillance between infusions. The nurses and pharmacists should regularly check immune titers to monitor immunosuppression. While there are no reported cases of progressive multifocal leukoencephalopathy (PML) to date (which has happened in other anti-CD20 antibodies and immunosuppressant therapies), the entire healthcare team must be on the lookout for clinical signs and symptoms, including hemiparesis, clumsiness, visual changes, memory/thinking changes, and personality changes.<xref ref-type="bibr" rid="article-41457.r12">[12]</xref> The clinical trial experience showed a higher rate of breast malignancy in the ocrelizumab-treated group. However, patients are not advised to undergo increased surveillance and continue to undergo routine breast cancer screening as age-appropriate.<xref ref-type="bibr" rid="article-41457.r13">[13]</xref></p>
        <p>Pharmacists should also work with the prescriber and nursing to ensure proper dosing, preclude drug interactions, and educate the patient and nursing staff on potential adverse reactions. This information will allow nursing to administer the drug effectively and monitor for any adverse reactions and inform the ordering clinician should they encounter any concerns. This collaborative paradigm exemplifies the kind of interprofessional teamwork the healthcare team requires to administer ocrelizumab effectively to achieve optimal patient outcomes while minimizing patient risks. [Level 5]</p>
        <p>Finally, the drug is prohibitively expensive, and insurance health plans do not always cover the cost. Without long-term data available, clinicians should always consider other similar cost-effective agents first.</p>
        <p>Interprofessional communication between the primary treatment team and the patient&#x02019;s primary care provider essential to make sure such screenings occur as estimates are that roughly one-third of women do not get an appropriate annual screening.<xref ref-type="bibr" rid="article-41457.r14">[14]</xref></p>
      </sec>
      <sec id="article-41457.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41457&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41457">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41457/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41457">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41457.s11">
        <title>References</title>
        <ref id="article-41457.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bar-Or</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Comi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Seze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giovannoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Hemmer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lublin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rammohan</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Selmaj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Traboulsee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masterman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fontoura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Belachew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mairon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wolinsky</surname>
                <given-names>JS</given-names>
              </name>
              <collab>ORATORIO Clinical Investigators</collab>
            </person-group>
            <article-title>Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Jan</month>
            <day>19</day>
            <volume>376</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-220</page-range>
            <pub-id pub-id-type="pmid">28002688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauser</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bar-Or</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Comi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giovannoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Hemmer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lublin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montalban</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rammohan</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Selmaj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Traboulsee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolinsky</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Klingelschmitt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masterman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fontoura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Belachew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mairon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kappos</surname>
                <given-names>L</given-names>
              </name>
              <collab>OPERA I and OPERA II Clinical Investigators</collab>
            </person-group>
            <article-title>Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Jan</month>
            <day>19</day>
            <volume>376</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-234</page-range>
            <pub-id pub-id-type="pmid">28002679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorensen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Blinkenberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-52</page-range>
            <pub-id pub-id-type="pmid">26788130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000f6;rner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>New approaches of B-cell-directed therapy: beyond rituximab.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2008</year>
            <month>May</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-8</page-range>
            <pub-id pub-id-type="pmid">18388516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stashenko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nadler</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schlossman</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Characterization of a human B lymphocyte-specific antigen.</article-title>
            <source>J Immunol</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>125</volume>
            <issue>4</issue>
            <fpage>1678</fpage>
            <page-range>1678-85</page-range>
            <pub-id pub-id-type="pmid">6157744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Grillo-L&#x000f3;pez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varns</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.</article-title>
            <source>Biochem Soc Trans</source>
            <year>1997</year>
            <month>May</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>705</fpage>
            <page-range>705-8</page-range>
            <pub-id pub-id-type="pmid">9191187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avasarala</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is Overkill.</article-title>
            <source>Drug Target Insights</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>1177392817737515</fpage>
            <pub-id pub-id-type="pmid">29123374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciardi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Iannetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zingaropoli</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Salpini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aragri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Annecca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pontecorvo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Altieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Svicher</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mastroianni</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Vullo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>ofy356</fpage>
            <pub-id pub-id-type="pmid">30697576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conte</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Dellaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>27</volume>
            <fpage>397</fpage>
            <page-range>397-399</page-range>
            <pub-id pub-id-type="pmid">30508784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fragoso</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Adoni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JBB</given-names>
              </name>
              <name>
                <surname>Finkelsztejn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>da Gama</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Grzesiuk</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Parolin</surname>
                <given-names>MFK</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Vasconcelos</surname>
                <given-names>CCF</given-names>
              </name>
            </person-group>
            <article-title>Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children.</article-title>
            <source>Neurol Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-232</page-range>
            <pub-id pub-id-type="pmid">30167914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langer-Gould</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy and Family Planning in Multiple Sclerosis.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>773</fpage>
            <page-range>773-792</page-range>
            <pub-id pub-id-type="pmid">31162316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The clinical features of PML.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>78 Suppl 2</volume>
            <fpage>S8</fpage>
            <page-range>S8-12</page-range>
            <pub-id pub-id-type="pmid">22123935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenfield</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>B-cell Therapy for Multiple Sclerosis: Entering an era.</article-title>
            <source>Ann Neurol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-26</page-range>
            <pub-id pub-id-type="pmid">29244240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41457.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bleyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baines</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Impact of screening mammography on breast cancer mortality.</article-title>
            <source>Int J Cancer</source>
            <year>2016</year>
            <month>Apr</month>
            <day>15</day>
            <volume>138</volume>
            <issue>8</issue>
            <fpage>2003</fpage>
            <page-range>2003-12</page-range>
            <pub-id pub-id-type="pmid">26562826</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
